COVID-19 Switzerland
Information on the current situation, as of 22 November 2022
The key figures will be published each Tuesday at 15:30.
Vaccinations,Switzerland and Liechtenstein
Vaccinated people by canton of residence
The data published here is based on information provided to us regularly by the cantons and the Principality of Liechtenstein. We publish the numbers each Tuesday. Therefore, they may differ from the numbers communicated by the cantons and Liechtenstein. The figures cover vaccines from all manufacturers.
Several vaccines for preventing COVID-19 are authorised in Switzerland and Liechtenstein. A booster vaccination with an mRNA vaccine from Moderna (Spikevax®) or Pfizer/BioNTech (Comirnaty®) and the Novavax (Nuvaxovid®) vaccine is recommended at the earliest four months after the last vaccine or after infection for everyone aged 16 or older. More information on the recommended vaccines and the time period between vaccines can be found on the FOPH website > Coronavirus: vaccination.
Information on adverse vaccination reactions (AVRs) is collected via Swissmedic’s spontaneous reporting system. Swissmedic reviews and evaluates the reported side effects. More details can be found on the Swissmedic website. Recently, the time frame desired can be selected with the slider below the graph.
Geographical distribution
Vaccinated people by canton of residence, Switzerland and Liechtenstein, Status: 21.11.2022
Switzerland and Liechtenstein
Total population, Status: 21.11.2022| People with at least one dose | 6 116 442 | 69,68% |
|---|---|---|
| Vaccinated in the last six months | 939 857 | 10,71% |
Development over time
Vaccinated people, Switzerland and Liechtenstein, 21.12.2020 to 21.11.2022
Recently, the time frame desired can be selected with the slider below the graph.
Demography
Vaccinated people, Switzerland and Liechtenstein, 21.12.2020 to 21.11.2022
Recently, the time frame desired can be selected with the slider below the graph.
Distribution by age group
Switzerland and Liechtenstein
0–9
3,70% (0,20%)
10–19
50,34% (2,54%)
20–29
73,35% (3,91%)
30–39
73,55% (5,13%)
40–49
77,85% (6,52%)
50–59
81,18% (9,17%)
60–69
84,74% (17,73%)
70–79
90,56% (30,13%)
80+
93,03% (44,41%)